Please see the data submission section of the protocol for further instructions. Do not submit study data or forms to the CTSU Data Operations. Do not copy the CTSU on data submission. The study protocol and all related forms and documents must be downloaded from the protocol- specific Web page of the CTSU Member Web site located at https://www.ctsu.org . Sites must use the current form version and adhere to the instructions and submission schedule outlined in the protocol. CITN sites should follow procedures outlined in the pr otocol for Site registration, Patient Enrollment, Adverse Event Reporting, Data Submission (including ancillary studies), and Drug Procurement. For questions unrelated to patient eligibility, treatment, or data submission contact the CTSU Help Desk by phone or e-mail: CTSU General Information Line – 1-888-823-5923, or ctsucontact@westat.com . All calls and correspondence will be triaged to the appropriate CTSU representative. For detailed information on the regulatory and monitoring procedures for CTSU sites please review the CTSU Regulatory and Monitoring Procedur es policy located on the CTSU members’ website https://www.ctsu.org The CTSU Web site is located at https://www.ctsu.org NCI Protocol #: CITN-04 Version Date: 27 Jan 2016 4 SCHEMA Cohort INCB024360 Dosing MELITAC 12.1 Dosing Blood draws Tumor biopsies including FNA A Pts.enrolled >6 wks after failing anti- PD-1/PDL-1 300 mg po bid continuous for 98 days (3 months) Intradermal/subcutaneous Days 21, 28, 35, 56, 77, 98 (Weeks 3, 4, 5, 8, 11, and 14) Pretreatment day 0 and on days 21, 42, 98, and 112 Days 0, 21, 42, and (optional day 112) and (optional when coming off study including for progression) B Pts.enrolled 2-6 wks after failing anti- PD-1/PDL-1 100 mg po bid continuous for 98 days (3 months) Intradermal/subcutaneous Days 21, 28, 35, 56, 77, 98 (Weeks 3, 4, 5, 8, 11, and 14) Pretreatment day 0 and on days 21, 42, 98, and 112 Days 0, 21, 42, and (optional day 112) and (optional when coming off study including for progression) All other pts . 300 mg po bid Intradermal/subcutaneous Days 21, 28, 35, 56, 77, 98 (Weeks 3, 4, 5, 8, 11, and 14) Pretreatment day 0 and on days 21, 42, 98, and 112 Days 0, 21, 42, and (optional day 112) and (optional when coming off study including for progression Abbreviations: bid, twice per day; FNA, fine-needle aspiration; po, orally; pre-tx, pretreatment; SC, subcutaneous All other patients enrolled who have not been treated with anti-PD1/PDL- 1 will receive 300 mg BID INCB024360 NCI Protocol #: CITN-04 Version Date: 27 Jan 2016 5 TABLE OF CONTENTS SCHEMA ……………………………………………………………………………..4 1. OBJECTIVES ....................................................................................................................